Statins as Anticancer Agents in the Era of Precision Medicine
Abstract
Statins are widely prescribed cholesterol-lowering drugs that inhibit HMG-CoA reductase (HMGCR), the rate-limiting enzyme of the mevalonate metabolic pathway. Multiple lines of evidence indicate that certain cancers depend on the mevalonate pathway for growth and survival, and, therefore, are vulnerable to statin therapy. However, these immediately available, well-tolerated, and inexpensive drugs have yet to be successfully repurposed and integrated into cancer patient care. In this review, we highlight recent advances and outline important considerations for advancing statins to clinical trials in oncology.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Nov 13, 2020
- Source ID
- 10.1158/1078-0432.ccr-20-1967
Entities
People
- Emily Branchard
- Jenna E van Leeuwen
- Joseph Longo
- Linda Z Penn
- Mohamad Elbaz
Organizations
- Canadian Breast Cancer Foundation
- Canadian Institutes of Health Research
- University of Toronto